Inspire Medical Systems stock has endured a steep share price decline over the past three years, yet the current intrinsic value checks, including a Discounted Cash Flow (DCF) estimate, point to a company that screens as undervalued relative to where the market is pricing it today.

• The share price is down 73.8% over three years, which means current buyers are assessing a very different risk and return profile than investors who bought at earlier highs.
• The DCF estimate indicates the stock trades at roughly a 34.0% discount to intrinsic value, although this relies on the company meeting future cash flow expectations that may not be guaranteed.
• The broader valuation work suggests the shares are cheap on most measures, with the company scoring well on value checks in 5 of 6 areas at this valuation summary.

The issue now is whether Inspire Medical Systems deserves to trade closer to that intrinsic value estimate, or whether the prolonged share price decline is signaling risks that the current valuation models are not fully capturing.

Is Inspire Medical Systems Still Cheap on Cash Flow?

The Discounted Cash Flow model estimates what Inspire Medical Systems could be worth based on its forecast cash generation to shareholders. For Inspire Medical Systems, the latest twelve month free cash flow sits at about $116.4 million, and the projections used in the model assume cash flows that broadly level off rather than showing rapid expansion or collapse.

Using these inputs, the model points to an estimated intrinsic value of about $86.53 per share. That is roughly 34.0% above where the market is currently pricing the stock, which indicates that the cash flow outlook incorporated into this DCF is more optimistic than the sentiment implied by the share price. The picture that emerges is of a company that the model suggests is undervalued on a cash generation basis, although this depends on the projected free cash flows being achieved over time.

Overall, the DCF work suggests Inspire Medical Systems stock currently screens as undervalued relative to its modeled intrinsic value.

Our Discounted Cash Flow (DCF) analysis suggests Inspire Medical Systems is undervalued by 34.0%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.

Does Inspire Medical Systems Look Undervalued on Earnings?

The P/E ratio is a useful cross check for Inspire Medical Systems because it ties the share price directly to the earnings that support it. For Inspire Medical Systems, the current P/E sits at about 12.2x, which is well below the Medical Equipment industry average of around 26.2x and a peer group average near 36.8x.

In addition to that simple comparison, a fair P/E multiple of roughly 18.3x has been estimated for Inspire Medical Systems based on its sector, earnings profile and risk. The current 12.2x level is meaningfully under that fair ratio, which indicates the stock trades at a discount even after accounting for those factors rather than just against broad industry benchmarks.

Based on the P/E multiple alone, Inspire Medical Systems stock appears undervalued compared with both its tailored fair ratio and typical peers in the Medical Equipment sector.

The Inspire Medical Systems Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Inspire Medical Systems pick up where the valuation work leaves off and focus on the future that current pricing implies. They set out the growth, margin and earnings paths that would need to hold for Inspire Medical Systems' stock to be worth materially more or less than today's price, and turn each single valuation output into a set of assumptions you can follow over time on the company's Community page.

Community views on Inspire Medical Systems now sit at opposite ends of the spectrum, with one side focused on procedure and reimbursement upside and the other on coding and product concentration risk.

Bull case: 30% undervalued

"The full conversion to Inspire V has already resulted in over 20% increases in implant volumes at transitioned centers, and as more centers adopt, system-wide procedure growth could significantly exceed consensus expectations..."

Bear case: 46% overvalued

"The accelerating preference for at-home or non-implant digital sleep solutions may erode Inspire's addressable market and put sustained pressure on procedure volumes, thereby constraining revenue expansion..."

Do you think there's more to the story for Inspire Medical Systems? Head over to our Community to see what others are saying!

The Bottom Line

For Inspire Medical Systems, both the Discounted Cash Flow (DCF) intrinsic value estimate and the P/E comparison point to a stock that screens as undervalued rather than stretched. The broader checks also lean supportive, which suggests the current discount reflects uncertainty more than clear evidence that the business is permanently impaired.

What matters now is whether Inspire Medical Systems can deliver the cash flows and earnings path implied in the intrinsic value work without data showing a sustained deterioration in procedure volumes or pricing. The key question for investors is whether today's discount is compensation for real reimbursement and product concentration risk or an opportunity if those risks prove manageable.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.